Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06093425 | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma | not yet recruiting | Phase 3 | 820 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT06203600 | Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | recruiting | Phase 2 / Phase 3 | 224 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 |
| clinicaltrials |
| NCT06608927 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(PRISM-1) | active not recruiting | Phase 3 | 610 | Arcus Biosciences, Inc.INDUSTRY | 13 | Sep 29, 2026 | clinicaltrials |
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors(STELLAR-311) | recruiting | Phase 2 / Phase 3 | 440 | ExelixisINDUSTRY | 17 | Sep 29, 2026 | clinicaltrials |
| NCT07265674 | A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer(Beacon-BTC) | recruiting | Phase 3 | 480 | J-Pharma Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04415853 | Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer | recruiting | Phase 3 | 416 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04793958 | Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) | active not recruiting | Phase 3 | 461 | Mirati Therapeutics Inc.INDUSTRY | 32 | Sep 28, 2026 | clinicaltrials |
| NCT06958432 | Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) | recruiting | Phase 2 / Phase 3 | 430 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT07221253 | A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)(AB02) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 19 | Sep 28, 2026 | clinicaltrials |
| NCT07222800 | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | recruiting | Phase 3 | 800 | PfizerINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )(RASolute 305) | recruiting | Phase 3 | 670 | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07691762 | A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 690 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05610163 | Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing Response(JANUS) | active not recruiting | Phase 2 / Phase 3 | 760 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06618664 | A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) | recruiting | Phase 3 | 590 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06662786 | A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer(OrigAMI-2) | recruiting | Phase 3 | 1,000 | Janssen Research & Development, LLCINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT06750094 | A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy(OrigAMI-3) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT06989437 | A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | recruiting | Phase 2 / Phase 3 | 982 | PfizerINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT07218926 | A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy | recruiting | Phase 3 | 450 | GlaxoSmithKlineINDUSTRY | 19 | Sep 25, 2026 | clinicaltrials |
| NCT07271355 | Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial | recruiting | Phase 3 | 129 | City of Hope Medical CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07562152 | Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(MAPKeeper 301) | recruiting | Phase 3 | 510 | Immuneering CorporationINDUSTRY | 4 | Sep 25, 2026 | clinicaltrials |
| NCT07842172 | Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms(REMAIN) | not yet recruiting | Phase 3 | 240 | Washington University School of MedicineOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05152147 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers(HERIZON-GEA-01) | active not recruiting | Phase 3 | 920 | Jazz PharmaceuticalsINDUSTRY | 33 | Sep 24, 2026 | clinicaltrials |
| NCT05752136 | Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma | recruiting | Phase 3 | 108 | Sir Run Run Shaw HospitalOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05863195 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | recruiting | Phase 3 | 408 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07221357 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 990 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 23, 2026 | clinicaltrials |
| NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 304) | recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 9 | Sep 23, 2026 | clinicaltrials |
| NCT07836530 | Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 492 | BeOne MedicinesINDUSTRY | 0 | Sep 23, 2026 | clinicaltrials |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | active not recruiting | Phase 3 | 298 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06109272 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-2) | active not recruiting | Phase 2 / Phase 3 | 89 | AbbVieINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | recruiting | Phase 3 | 614 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07132463 | Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study | recruiting | Phase 3 | 196 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07750158 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease(STELLAR-316) | recruiting | Phase 3 | 600 | ExelixisINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT02851784 | Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma | recruiting | Phase 2 / Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05043688 | Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | active not recruiting | Phase 3 | 426 | Zhigang LiOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06361888 | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 502 | HutchmedINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07027436 | Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.(DARTS) | recruiting | Phase 3 | 30 | Hamilton Health Sciences CorporationOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07217704 | Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.(FAPI-GO) | recruiting | Phase 3 | 200 | SOFIEINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07823049 | Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy | recruiting | Phase 3 | 226 | Evopoint Biosciences Inc.INDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07823348 | JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer | not yet recruiting | Phase 3 | 560 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02523443 | Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection | active not recruiting | Phase 3 | 231 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05720338 | Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | recruiting | Phase 3 | 234 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06007846 | A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer | recruiting | Phase 2 / Phase 3 | 12 | Inova Health Care ServicesOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06246344 | Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer | active not recruiting | Phase 3 | 128 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07087054 | Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen(CAREFNDR) | recruiting | Phase 3 | 141 | Crinetics Pharmaceuticals Inc.INDUSTRY | 14 | Sep 15, 2026 | clinicaltrials |
| NCT07284849 | A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | recruiting | Phase 3 | 700 | Incyte CorporationINDUSTRY | 22 | Sep 15, 2026 | clinicaltrials |
Data updated 16 hours agoSource updated Sep 29, 2026source: clinicaltrials